drugset / Trial / NCT05221892

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

NCT05221892

Phase 4 Completed 334 enrolled Fundação Educacional Serra dos Órgãos
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.

Timeline

Start
2021-11-22
Primary completion
2023-03-31
Completion
2023-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CALCIUM PHOSPHATE, DIBASIC Small molecule 50 mg Oral
Subject Gamma-Aminobutyric Acid Small molecule 100 mg Oral
Comparator Ginger Traditional medicine (herbal / TCM) 160 mg Oral
Subject Glutamic Acid Unknown 100 mg Oral
Subject Pyridoxine Unknown 10 mg Oral
Subject Thiamine Other / unclassified 25 mg Oral
Subject Vitamin B12 Other / unclassified 5 ug Oral

Indications

No indication recorded.